Navigation Links
Novel Product for Post Surgical Scar Formation Entering Clinical Development
Date:1/21/2009

GOTEBORG, Sweden, January 21 /PRNewswire/ -- PharmaSurgics AB has received approval from the Swedish medical product agency to proceed to phase I clinical documentation with the novel candidate drug, PXL01, indicated for post-surgical adhesion prevention. The clinical program will be initiated in March 2009.

Adhesions are bands of scar tissue that connect anatomic structures that should not normally be connected. These develop when the body's repair mechanisms respond to tissue injury as the result of surgical trauma. Adhesions form after almost any type of surgery and are a significant source of post-surgical complications for millions of patients, a major burden for surgeons and a great economic load on the healthcare systems.

Currently the problem does not have any satisfying solution and there is a great need for new products. PharmaSurgics patented drug candidate (PXL01) has demonstrated an excellent effect and safety profile in preclinical studies and the first clinical trial on patients are planned to start in the end of 2009. PharmaSurgics goal is to be first to market with a pharmacological product for the prevention of post-surgical adhesions.

About PharmaSurgics

PharmaSurgics in Sweden AB is a Gothenburg based biotech company that develops and commercializes a novel treatment for preventing harmful scarring and promoting wound healing after surgery. PharmaSurgics product concept is based on proprietary synthetic peptides which have strong anti-inflammatory and anti-infectious properties. The company was founded in 2005, based on extensive research by Dr. Inger Mattsby- Baltzer and Professor Kjell Olmarker at Sahlgrenska University Hospital, Goteborg, Sweden. PharmaSurgics is part of the Karolinska Development portfolio.

    For further information please contact Fredrik Sjovall, CEO of
    PharmaSurgics

    Phone: +46-31-762-29-01
    Email: fredrik@pharmasurgics.se



'/>"/>
SOURCE PharmaSurgics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
2. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
3. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
4. Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
5. Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders
6. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
7. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
8. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
9. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
10. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
11. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... February 10, 2016 --> --> This ... .  --> Japan .  --> A separate ... With submission, Shire continues to strengthen its ... submission, Shire continues to strengthen its presence ... Shire continues to strengthen its presence ...
(Date:2/10/2016)... -- CSI Specialty Group (CSI) expanded its specialty pharmacy ... Pharmacy Podcast. A free, weekly show, the Specialty Pharmacy ... discussion and context amongst specialty pharmacy peers and professionals. ... The Specialty Pharmacy Podcast, hosted by industry leader ... DiMascio, CHE, CMCE, CPC, is available for streaming and/or ...
(Date:2/10/2016)... , Feb. 10, 2016  CVS Health (NYSE: ... people living in Santa Clara County, CA ... B on the Santa Clara University campus. CVS Pharmacy ... to protect patients against the disease. Students at Santa ... to get vaccinated. In addition, anyone who has had ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... ... health care communications company offering education, research and medical media, has launched ... specialists working in infectious diseases. , As the all-inclusive resource for infectious ...
(Date:2/10/2016)... Walton Beach, Florida (PRWEB) , ... February 10, ... ... the innovative weather-forecasting company is unveiling its revolutionary new 2.0 version at the ... platform, MetLoop has “put the power of the world's most advanced weather technology ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting , a ... partnered with Heart City Health Center to improve access to language ... City Health Center has provided the Elkhart community with access to high quality, ...
(Date:2/10/2016)... ... 10, 2016 , ... Compliancy Group LLC is pleased to ... throughout the country. The Guard was specifically designed to handle each element required ... regulatory updates, and compliance coaching. , In addition to meeting the compliance needs ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Emergency rooms provide ... to find. Unfortunately, this can leave patients with dental emergencies at risk of losing ... now offering emergency dental care. , Common dental emergencies include:, ...
Breaking Medicine News(10 mins):